Qiang Wang

Qiang Wang

Auto-generated profile, based on publicly available information

Qiang Wang

The State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, China; Department of Thoracic Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2019 in eLife
Verified
Journal Article
Open access
WGWenna Guo
Wenna Guo
LZLiucun Zhu
Liucun Zhu
RZRui Zhu
Rui Zhu
QCQihan Chen
Qihan Chen
QWQiang Wang
Qiang Wang
JCJian-Qun Chen
Jian-Qun Chen
Cutaneous melanoma (CM) is a life-threatening form of skin cancer. Prognostic biomarkers can reliably stratify patients at initial melanoma diagnosis according to risk, and may inform clinical decisions. Here, we performed a retrospective, cohort-based study analyzing genome-wide DNA methylation of 461 patients with CM from the TCGA database. Cox regression analyses were conducted to establish a four-DNA methylation signature that was significantly associated with the overall survival (OS) of patients with CM, and that was validated in an independent cohort. Corresponding Kaplan–Meier analysis displayed a distinct separation in OS. The ROC analysis confirmed that the predictive signature performed well. Notably, this signature exhibited much higher predictive accuracy in comparison with known biomarkers. This signature was significantly correlated with immune checkpoint blockade (ICB) immunotherapy-related signatures, and may have potential as a guide for measures of responsiveness to ICB immunotherapy.

20 November 2020 in Journal of Systematics and Evolution
Verified
Journal Article
Closed access
PDF file
Jia-Yu XueJia-Yu Xue
Jia-Yu Xue
SDShan‐Shan Dong
Shan‐Shan Dong
MWMing‐Qiang Wang
Ming‐Qiang Wang
TSTian‐Qiang Song
Tian‐Qiang Song
GZGuang‐Can Zhou
Guang‐Can Zhou
YHYueyu Hang
Yueyu Hang

16 November 2018 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
WGWenna Guo
Wenna Guo
LZLiucun Zhu
Liucun Zhu
MYMinghao Yu
Minghao Yu
RZRui Zhu
Rui Zhu
QCQihan Chen
Qihan Chen
QWQiang Wang
Qiang Wang
Ovarian cancer is the most fatal tumor of the female reproductive system and the fifth leading cause of cancer death among women in the USA. The prognosis is poor due to the lack of biomarkers for treatment options. The methylation array data of 551 patients with ovarian serous cystadenocarcinoma (OSC) in The Cancer Genome Atlas (TCGA) database were assessed in this study to explore the methylation biomarkers associated with prognosis and improve the prognosis of patients. These patients were divided into training (first two thirds) and validation datasets (remaining one third). A five-DNA methylation signature was found to be significantly associated with the overall survival of patients with OSC using the Cox regression analysis in the training dataset. The Kaplan–Meier analysis showed that the five-DNA methylation signature could significantly distinguish the high- and low-risk patients in both training and validation sets. The receiver operating characteristic (ROC) analysis further confirmed that the five-DNA methylation signature exhibited high sensitivity and specificity to predict the prognostic survival of patients. Also, the five-DNA methylation signature was not only applicable in patients of different ages, stages, histologic grade, and size of residual tumor after surgery but also more accurate in predicting OSC prognosis compared with known biomarkers. This five-DNA methylation signature demonstrated the potential of being a novel independent prognostic indicator and served as an important tool for guiding the clinical treatment of OSC to improve outcome prediction and management for patients. Hence, the findings of this study might have potential clinical significance.

1 March 2017 in Journal of Dermatological Science
Verified
Journal Article
Closed access
XCXijia Chen
Xijia Chen
WGWenna Guo
Wenna Guo
XXXin-Jian Xu
Xin-Jian Xu
FSFangchu Su
Fangchu Su
YWYi Wang
Yi Wang
LZLiucun Zhu
Liucun Zhu

10 October 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
WGWenna Guo
Wenna Guo
XCXijia Chen
Xijia Chen
LZLiucun Zhu
Liucun Zhu
QWQiang Wang
Qiang Wang
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Wenna Guo1, Xijia Chen2, Liucun Zhu2 and Qiang Wang1 1State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, China 2School of Life Sciences, Shanghai University, Shanghai, China Correspondence to: Qiang Wang, email: wangq@nju.edu.cn Liucun Zhu, email: zhuliucun@shu.edu.cn Keywords: biomarker, HNSCC, prognosis, risk-stratification, RNA-seq Received: August 18, 2017 Accepted: September 22, 2017 Published: October 10, 2017 ABSTRACT Head and neck squamous cell carcinoma (HNSCC), one of the most common cancers with high morbidity and mortality rates worldwide, has a poor prognosis. The transcriptome sequencing data of 500 patients with HNSCC in the TCGA dataset were assessed to find biomarkers associated with HNSCC prognosis so as to improve the prognosis of patients with HNSCC. The patients were divided into the training and testing sets. A model of six mRNAs (FRMD5, PCMT1, PDGFA, TMC8, YIPF4, ZNF324B) that could predict patient prognosis was identified in the training set using the Cox regression analysis. According to this model, the patients were divided into high-risk and low-risk groups. The Kaplan-Meier analysis showed that the high-risk group showed significantly shorter overall survival time compared with the low-risk group in both training and testing sets. The receiver operating characteristic analysis further confirmed high sensitivity and specificity for the model, which was more accurate compared with some known biomarkers in predicting HNSCC prognosis. Moreover, the model was applicable to patients of different ages, genders, clinical stages, tumor locations, smoking history, and human papillomavirus (HPV) status, as well as to microarray dataset. This model could be used as a novel biomarker for the prognosis of HNSCC and a significant tool for guiding the clinical treatment of HNSCC. The risk score acquired from the model might contribute to improving outcome prediction and management for patients with HNSCC, indicating its clinical significance.

11 October 2015 in Computational and Mathematical Methods in Medicine
Verified
Journal Article
Open access
PDF file
YZYueping Zhan
Yueping Zhan
WGWenna Guo
Wenna Guo
YZYing Zhang
Ying Zhang
QWQiang Wang
Qiang Wang
XXXin-Jian Xu
Xin-Jian Xu
LZLiucun Zhu
Liucun Zhu
Kidney renal clear cell carcinoma (KIRC) is one of the most common cancers with high mortality all over the world. Many studies have proposed that genes could be used to predict prognosis in KIRC. In this study, RNA expression data from next-generation sequencing and clinical information of 523 patients downloaded from The Cancer Genome Atlas (TCGA) dataset were analyzed in order to identify the relationship between gene expression level and the prognosis of KIRC patients. A set of five genes that significantly associated with overall survival time was identified and a model containing these five genes was constructed by Cox regression analysis. By Kaplan-Meier and Receiver Operating Characteristic (ROC) analysis, we confirmed that the model had good sensitivity and specificity. In summary, expression of the five-gene model is associated with the prognosis outcomes of KIRC patients, and it may have an important clinical significance.